Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1995 1
2005 1
2011 1
2012 1
2015 1
2016 1
2018 1
2020 1
2021 1
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Renal Pelvis Urothelial Carcinoma"
Page 1
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
OBJECTIVE: Real-world evidence regarding enfortumab vedotin for unresectable or metastatic urothelial carcinoma is scarce, particularly in Japan. We investigated real-world data focusing on patient background, previous treatments, response, survival and adver …
OBJECTIVE: Real-world evidence regarding enfortumab vedotin for unresectable or metastatic urothelial carcinoma is scar …
Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G, Ouzaid I, Verze P, Hermieu JF, Mirone V, Xylinas E. Califano G, et al. World J Urol. 2021 May;39(5):1357-1367. doi: 10.1007/s00345-020-03502-7. Epub 2020 Oct 31. World J Urol. 2021. PMID: 33128595 Review.
INTRODUCTION: Immunotherapy is changing the way we think about and treat urothelial carcinoma (UC). The PD-1/PD-L1 pathway inhibition has shown robust efficacy, associated with an acceptable toxicity profile, in patients with locally advanced and metastatic unres …
INTRODUCTION: Immunotherapy is changing the way we think about and treat urothelial carcinoma (UC). The PD-1/PD-L1 pathway inh …
Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Iida K, Inoue K, Tachibana A, Yoshikawa T, Sakamoto K, Ohnishi M, Maesaka F, Takamatsu N, Mieda K, Ohmori C, Matsubara T, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Int J Clin Oncol. 2024 Sep;29(9):1311-1325. doi: 10.1007/s10147-024-02573-5. Epub 2024 Jun 18. Int J Clin Oncol. 2024. PMID: 38888683
BACKGROUND: Maintenance avelumab is currently recommended for patients with unresectable and/or metastatic (mUC) achieving at least stable disease (SD) on first-line platinum-based chemotherapy (1L-CT). Pembrolizumab is an alternative therapeutic avenue for this patient co …
BACKGROUND: Maintenance avelumab is currently recommended for patients with unresectable and/or metastatic (mUC) achieving at least s …
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
BACKGROUND: Nivolumab is used after platinum-based chemotherapy in patients with metastatic urothelial carcinoma. Studies suggest improved outcomes for dual checkpoint inhibition with high ipilimumab doses. ...Adults aged 18 years or older with histologically confir …
BACKGROUND: Nivolumab is used after platinum-based chemotherapy in patients with metastatic urothelial carcinoma. Studies sugg …
Newer developments in the therapeutics of the transitional cell carcinoma of renal pelvis.
Dasanu CA, Ong-Bacay A, Codreanu I. Dasanu CA, et al. J Oncol Pharm Pract. 2012 Mar;18(1):97-103. doi: 10.1177/1078155210394695. Epub 2011 Jan 19. J Oncol Pharm Pract. 2012. PMID: 21248173 Review.
Many of the risk factors and pathogenesis of urothelial carcinoma of the renal pelvis are similar to the ones of the more common urothelial bladder cancer. ...The role of adjuvant radiation and chemoradiation for carcinoma of the renal …
Many of the risk factors and pathogenesis of urothelial carcinoma of the renal pelvis are similar to the ones of …
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Tully CM, Apolo AB, Zabor EC, Regazzi AM, Ostrovnaya I, Furberg HF, Rosenberg JE, Bajorin DF. Tully CM, et al. Cancer. 2016 Mar 1;122(5):712-21. doi: 10.1002/cncr.29801. Epub 2015 Nov 30. Cancer. 2016. PMID: 26618338 Free PMC article.
BACKGROUND: The current study compared the incidence of vascular thromboembolic events (VTEs) in patients with metastatic or unresectable urothelial carcinoma (UC) who were treated with gemcitabine and carboplatin (GCb); gemcitabine, carboplatin, and bevacizu …
BACKGROUND: The current study compared the incidence of vascular thromboembolic events (VTEs) in patients with metastatic or unresectable …
Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.
Logothetis CJ, Samuels ML, Ogden S, Dexeus FH, Swanson D, Johnson DE, von Eschenbach A. Logothetis CJ, et al. J Urol. 1985 Sep;134(3):460-4. doi: 10.1016/s0022-5347(17)47240-5. J Urol. 1985. PMID: 2993671
Histologically, the patients either had pure transitional cell carcinoma (29), transformation to a histological subtype of transitional cell carcinoma (7) or pure squamous cell carcinoma (2). ...Responses by histological sub …
Histologically, the patients either had pure transitional cell carcinoma (29), transformation to a histological subtype …
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP. Gray HJ, et al. Gynecol Oncol. 2018 Mar;148(3):507-514. doi: 10.1016/j.ygyno.2017.12.029. Epub 2018 Jan 17. Gynecol Oncol. 2018. PMID: 29352572 Clinical Trial.
METHODS: In this phase I study, patients with metastatic or unresectable solid tumors and 2 prior chemotherapy regimens received veliparib combined with carboplatin area under the curve (AUC) 4 on day 1 and gemcitabine 800mg/m(2) on days 1 and 8 of a 21-day cycle for maxim …
METHODS: In this phase I study, patients with metastatic or unresectable solid tumors and 2 prior chemotherapy regimens received veli …
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Artz A, Stadler WM, Vogelzang NJ, Zimmerman T, Ryan C. Artz A, et al. Am J Clin Oncol. 2005 Apr;28(2):109-13. doi: 10.1097/01.coc.0000142591.62299.8f. Am J Clin Oncol. 2005. PMID: 15803001 Clinical Trial.
We evaluated the toxicity and response rate of docetaxel and methotrexate (DM) followed by gemcitabine and cisplatin (GC) in patients with metastatic or unresectable transitional cell carcinoma of the urothelium. Patients received 3 cycles of DM (40 mg …
We evaluated the toxicity and response rate of docetaxel and methotrexate (DM) followed by gemcitabine and cisplatin (GC) in patients with m …
Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T. Igawa M, et al. Br J Urol. 1995 Sep;76(3):321-4. doi: 10.1111/j.1464-410x.1995.tb07708.x. Br J Urol. 1995. PMID: 7551840
PATIENTS AND METHODS: Fifty-one patients (37 men and 14 women, median age 66 years, range 41-82) with inoperable or metastatic carcinoma of the bladder, ureter or renal pelvis were treated with M-VAC and their responses evaluated for up to 7 years. ...Therefo …
PATIENTS AND METHODS: Fifty-one patients (37 men and 14 women, median age 66 years, range 41-82) with inoperable or metastatic carcinoma …